Daré Bioscience (NASDAQ:DARE) Stock Crosses Below 200-Day Moving Average – Here’s Why

Daré Bioscience, Inc. (NASDAQ:DARE)’s share price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.65 and traded as low as $3.18. Daré Bioscience shares last traded at $3.20, with a volume of 23,719 shares.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a report on Tuesday, December 17th.

Daré Bioscience Stock Performance

The stock’s 50 day moving average price is $3.51 and its 200-day moving average price is $3.62. The company has a market cap of $28.45 million, a PE ratio of -5.54 and a beta of 1.27.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC increased its position in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 6.70% of the company’s stock.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.